Mucocort AB strengthens global position with Australian Patent

Press release -

Mucocort AB strengthens global position with Australian Patent

Mucocort AB has successfully developed M045A, an innovative mucoadhesive "patch" for the treatment of oral aphthous ulcers. The company has now been granted a patent in Australia for its medical technology innovation, marking a significant milestone in its international expansion.

– "Securing a patent in Australia is a strategic achievement for Mucocort AB and a crucial step in our efforts to establish a presence in a key market. This strengthens our global position and unlocks new growth opportunities," says Jean Lycke, Project Manager at Mucocort AB.

The patent grants Mucocort AB exclusive rights in the Australian market, known for its advanced healthcare sector. It also paves the way for strategic collaborations with leading medtech companies, further accelerating the company’s expansion and market presence.

Mucocort receives business support from Umeå Biotech Incubator.

For more info, please contact:
Jean Lycke, Project Manager
Email; jl@emerentiagruppen.co
Mobile: +46702771511

Topics

Categories

Umeå Biotech Incubator (UBI) is one of Sweden’s state-of-the-art business incubators within the life sciences. We help researchers to use their data to the benefit of patients and citizens, improving their health. We support and train entrepreneurs in the fields of pharmaceuticals, diagnostics and medical engineering, and act as a bridge between academia, medicine and the business community.

Contacts

Related media

Download images for media use

Related content

  • Mucocort AB is developing an innovative mucoadhesive "patch" for mouth ulcers (aphthous stomatitis), one of the most common oral mucosal diseases. The Chinese patent secures Mucocort's technology in one of the largest markets globally.

    Mucocort receives additional patent approval for its innovative patch technology

    The Swedish MedTech company Mucocort AB has been granted a patent in China for its innovative product/technology, which has previously been approved under the European Patent System (EPC). Mucocort develops a mucoadhesive "patch" for mouth ulcers (aphthous stomatitis), one of the most common oral mucosal diseases.

  • Mucocort, business supported by Umeå Biotech Incubator, will initiate a clinical trial of their intraoral patch. The clinical trial will be conducted in collaboration with Oral Care AB and the production is managed by Aurena Laboratories AB.

    Mucocort initiates clinical trial of innovative patch for aphthous stomatitis

    Mucocort AB has received approval to start a clinical trial for an intraoral patch (M045A) to treat aphthous stomatitis, a condition causing mouth ulcers. The patch aims for immediate pain relief and healing promotion. The trial will be conducted in collaboration with Oral Care AB and produced by Aurena Laboratories AB in Sweden.

Umeå Biotech Incubator Enter your email address to follow Umeå Biotech Incubator

When you choose to create a user account and follow a newsroom your personal data will be used by us and the owner of the newsroom, for you to receive news and updates according to your subscription settings.

To learn more about this, please read our Privacy Policy, which applies to our use of your personal data, and our Privacy Policy for Contacts, which applies to the use of your personal data by the owner of the newsroom you follow.

Please note that our Terms of Use apply to all use of our services.

You can withdraw your consent at any time by unsubscribing or deleting your account.
Umeå Biotech Incubator Check your inbox

Email sent to __email__. Click the link there to follow Umeå Biotech Incubator.

Okay